07:12 AM EDT, 05/10/2024 (MT Newswires) -- MacroGenics ( MGNX ) late on Thursday said that five patients have died in the ongoing mid-stage study of its experimental drug to treat a type of prostate cancer, sending shares down by 65%.

Of the five patients, one died from acute myocardial infarction, one from cardiac arrest, two from pneumonitis, and one due to pleural effusion.

MacroGenics ( MGNX ) is undertaking the initial steps necessary to prepare for the potential initiation of a Phase 3 study in 2025, but the final decision to pursue the study will be based on an analysis of the final data set when available, the company said.

Price: 4.88, Change: -9.79, Percent Change: -66.73